Oxbryta (voxelotor) treats sickle cell disease by inhibiting hemoglobin S polymerization and improving blood flow. It is commonly used in adults and children from 12 years of age. The medication is taken orally, once a day, and the recommended starting dose is 1500mg. Side effects may include nausea, headache, and diarrhea, and patients need to be monitored for any changes in hemoglobin levels. Clinical studies have revealed Oxbryta’s efficacy in improving hemoglobin levels, reducing painful crises, and increasing patient quality of life. It is a valuable treatment option for patients with sickle cell disease.